VKTX: Phase III obesity trials advanced, R&D spending rose, and cash reserves remain strong
Advanced phase III trials for both injectable and oral VK2735, with strong efficacy and safety data supporting further development. R&D expenses and net loss increased due to expanded clinical activity, but a robust cash position supports ongoing programs and infrastructure growth.Based on Viking T…